Abstract
Introduction Improvement of long-term outcomes in kidney transplantation remains one of the most pressing challenges, yet drug development is stagnating. Human genetics offers an opportunity for much-needed target validation in transplantation. Conflicting data exist about the effect of transforming growth factor-beta 1 (TGF-β1) on kidney transplant survival since TGF-β1 has pro-fibrotic and protective effects. We investigated the impact of a recently discovered functional TGBF1 polymorphism on kidney graft survival.
Methods We performed an observational cohort study analyzing recipient and donor DNA in 1,271 kidney transplant-pairs from the University Medical Center Groningen in The Netherlands and associated a low-producing TGBF1 polymorphism (rs1800472-C>T) with 5, 10, and 15-year death-censored kidney graft survival.
Results Donor genotype frequencies of rs1800472 in TGBF1 differed significantly between patients with and without graft loss (P=0.014). Additionally, the low-producing TGBF1 polymorphism in the donor was associated with an increased risk of graft loss following kidney transplantation (HR 2.12 for the T-allele; 95%-CI 1.18–3.79; P=0.012). The incidence of graft loss within 15 years of follow-up was 16.4% in the CC-genotype group and 31.6% in the CT-genotype group. After adjustment for transplant-related covariates, the association between the TGBF1 polymorphism in the donor and graft loss remained significant. In contrast, there was no association between the TGBF1 polymorphism in the recipient and graft loss.
Conclusion Kidney allografts possessing a low-producing TGBF1 polymorphism have a higher risk of late graft loss. Our study adds to a growing body of evidence that TGF-β1 is beneficial, rather than harmful, for kidney transplant survival.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was financially supported by the Graduate School of Medical Sciences of the University of Groningen.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The medical ethics committee of the University Medical Center Groningen approved the study under file number METc 2014 077.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared second author
Data Availability
Data is available upon request.
Abbreviations
- BPAR
- Biopsy-proven acute rejection
- CIT
- Cold ischemia time
- DBD
- Donation after circulatory death
- DCD
- Donation after brain death
- DGF
- Delayed graft function
- ESKD
- End-stage kidney disease
- HLA
- Human leukocyte antigen
- HR
- Hazard ratio
- PRA
- Panel-reactive antibody
- SMAD
- Small mothers against decapentaplegic homologue
- SNP
- Single-nucleotide polymorphism
- TGF-β
- Transforming growth factor beta
- TGF-β1
- Transforming growth factor beta 1
- TGFB1
- Transforming growth factor beta 1 gene
- WIT
- Warm ischemia time
